NOVELION THERAPEUTICS INC - COM NEW (NVLNF)

CUSIP: 67001K202

Q4 2017 13F Holders as of 31 Dec 2017

Type / Class
Equity / COM NEW
Total 13F shares
15,100,610
Share change
+686,204
Total reported value
$47,110,925
Put/Call ratio
219%
Price per share
$3.12
Number of holders
71
Value change
-$1,383,311
Number of buys
37
Number of sells
17

Quarterly Holders Quick Answers

What is CUSIP 67001K202?
CUSIP 67001K202 identifies NVLNF - NOVELION THERAPEUTICS INC - COM NEW in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of NOVELION THERAPEUTICS INC - COM NEW (NVLNF) as of Q4 2017

As of 31 Dec 2017, NOVELION THERAPEUTICS INC - COM NEW (NVLNF) was held by 71 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 15,100,610 shares. The largest 10 holders included EdgePoint Investment Group Inc., Broadfin Capital, LLC, ARMISTICE CAPITAL, LLC, Stonepine Capital Management, LLC, MORGAN STANLEY, Sarissa Capital Management LP, Healthcare Value Capital, LLC, BlackRock Inc., FMR LLC, and JW Asset Management, LLC. This page lists 71 institutional shareholders reporting positions in this security for the Q4 2017 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.